Bionano Genomics Net Worth
Bionano Genomics Net Worth Breakdown | BNGO |
Bionano Genomics Net Worth Analysis
Bionano Genomics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bionano Genomics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bionano Genomics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bionano Genomics' net worth analysis. One common approach is to calculate Bionano Genomics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bionano Genomics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bionano Genomics' net worth. This approach calculates the present value of Bionano Genomics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bionano Genomics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bionano Genomics' net worth. This involves comparing Bionano Genomics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bionano Genomics' net worth relative to its peers.
Enterprise Value |
|
To determine if Bionano Genomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bionano Genomics' net worth research are outlined below:
| Bionano Genomics generated a negative expected return over the last 90 days | |
| Bionano Genomics has high historical volatility and very poor performance | |
| Bionano Genomics has some characteristics of a very speculative penny stock | |
| Bionano Genomics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 36.12 M. Net Loss for the year was (232.49 M) with profit before overhead, payroll, taxes, and interest of 5.95 M. | |
| Bionano Genomics currently holds about 187.34 M in cash with (125.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Bionano Genomics stock hits 52-week low at 0.2 By Investing.com - Investing.com Australia |
Bionano Genomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bionano Genomics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bionano Genomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Bionano Genomics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bionano Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bionano Genomics backward and forwards among themselves. Bionano Genomics' institutional investor refers to the entity that pools money to purchase Bionano Genomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Archford Capital Strategies, Llc | 2024-09-30 | 69.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 62.4 K | Jane Street Group Llc | 2024-06-30 | 48.5 K | Susquehanna International Group, Llp | 2024-06-30 | 48.4 K | Inspire Advisors, Llc | 2024-09-30 | 37.3 K | Simplex Trading, Llc | 2024-06-30 | 29.5 K | Justinvest Llc | 2024-06-30 | 29 K | Golden State Equity Partners | 2024-09-30 | 26.5 K | Tower Research Capital Llc | 2024-06-30 | 25.8 K | Vanguard Group Inc | 2024-09-30 | 2.2 M | Geode Capital Management, Llc | 2024-09-30 | 882.9 K |
Follow Bionano Genomics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.29 M.Market Cap |
|
Project Bionano Genomics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.29) | (1.35) | |
| Return On Capital Employed | (1.88) | (1.98) | |
| Return On Assets | (1.08) | (1.14) | |
| Return On Equity | (2.42) | (2.54) |
When accessing Bionano Genomics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bionano Genomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bionano Genomics' profitability and make more informed investment decisions.
Evaluate Bionano Genomics' management efficiency
Bionano Genomics has return on total asset (ROA) of (0.3264) % which means that it has lost $0.3264 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3833) %, meaning that it created substantial loss on money invested by shareholders. Bionano Genomics' management efficiency ratios could be used to measure how well Bionano Genomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of November 2024, Return On Tangible Assets is likely to drop to -1.35. In addition to that, Return On Capital Employed is likely to drop to -1.98. At this time, Bionano Genomics' Net Tangible Assets are very stable compared to the past year. As of the 29th of November 2024, Non Currrent Assets Other is likely to grow to about 7.8 M, while Total Assets are likely to drop about 142.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.82 | 2.96 | |
| Tangible Book Value Per Share | 1.82 | 1.91 | |
| Enterprise Value Over EBITDA | (0.59) | (0.62) | |
| Price Book Value Ratio | 0.67 | 0.64 | |
| Enterprise Value Multiple | (0.59) | (0.62) | |
| Price Fair Value | 0.67 | 0.64 | |
| Enterprise Value | 269.1 M | 282.5 M |
At Bionano Genomics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 0.7138 | Revenue 36.6 M | Quarterly Revenue Growth (0.10) | Revenue Per Share 0.749 | Return On Equity (1.38) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bionano Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bionano Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bionano Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bionano Genomics time-series forecasting models is one of many Bionano Genomics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bionano Genomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Bionano Genomics Earnings per Share Projection vs Actual
Bionano Genomics Corporate Management
| Jonathan JD | General Secretary | Profile | |
| Donna Polizio | Global Access | Profile | |
| Klint Rose | Head Development | Profile | |
| Helene Klein | Chief Officer | Profile | |
| Sheila MBA | Vice Marketing | Profile | |
| Christopher Stewart | Chief Officer | Profile | |
| Jonathan Dixon | Global Legal | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionano Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.30) | Revenue Per Share 0.749 | Quarterly Revenue Growth (0.10) | Return On Assets (0.33) | Return On Equity (1.38) |
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.